BenchSci vs Illumina
Side-by-side comparison of AI visibility scores, market position, and capabilities
BenchSci is an AI-powered biomedical research intelligence platform used by 16 of the top 20 pharma companies; accelerates experiment design by analyzing millions of scientific papers and proprietary data to recommend validated reagents and.
About
BenchSci is a Toronto-based life sciences AI company founded in 2015 by Tom Leung, Elvis Wianda, Liran Belenzon, and David Chen. The company builds AI-powered research intelligence software that helps biomedical scientists — particularly at pharmaceutical and biotechnology companies — design better experiments faster, reduce failure rates, and avoid duplicating work that has already been done. BenchSci''s platform applies machine learning to analyze both published scientific literature (including open-access and licensed journal databases) and proprietary experimental data from its pharma clients, extracting structured information about reagent performance, experimental protocols, and biological targets to generate recommendations for researchers planning new experiments.
World's dominant DNA sequencing platform with ~80% market share; ~$4.34B FY2025 revenue. Powers clinical genomics, oncology diagnostics, and population-scale sequencing.
About
Illumina was founded in 1998 in San Diego and has grown into the undisputed leader in next-generation sequencing (NGS), with approximately 80% global market share across research and clinical applications. The company's sequencing-by-synthesis (SBS) chemistry and NovaSeq, NextSeq, and MiSeq instrument platforms have become the standard infrastructure for genomic research, clinical oncology, reproductive health, and infectious disease diagnostics worldwide.\n\nIllumina's business model combines high-margin consumable sales (flow cells, reagent kits) with instrument placements, creating a razor-and-blades recurring revenue structure. Its clinical sequencing segment showed accelerating growth in 2025, with clinical consumables revenue up 20% year-over-year in Q4. The company is expanding into spatial transcriptomics and multi-omics with new instruments unveiled at AGBT 2025, broadening its addressable market.\n\nIllumina reported $4.34 billion in FY2025 revenue and guides to $4.5–$4.6 billion for FY2026, with non-GAAP operating margins of ~23%. Having divested Grail (its liquid biopsy subsidiary) following regulatory pressure, Illumina is refocused on its core sequencing franchise and positioned to benefit from continued clinical adoption of genomic medicine.
Key Details
Capabilities & Ecosystem
Also Compare
Track AI Visibility in Real Time
Monitor how your brand performs across ChatGPT, Gemini, Perplexity, Claude, and Grok daily.